Menu

Microbiome-Centric Human Health: A Call for Systems Biology

The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps in developing personalized microbiome-based therapies. 

Sep 6, 2017
The Scientist Creative Services Team

Microbiome-Centric Human Health: A Call for Systems Biology from thescientistllc on Vimeo.

With 100 times the number of genes contained in the human genome, and an array of different cell types and functions, one can argue that members of our microbiome constitute an additional human organ system. Research to date has implicated microbial activity in autoimmune disease, cancer, and the obesity epidemic. As a major source of variability across people, understanding and altering an individual’s microbiome is both a challenge and novel avenue for personalized medicine and nutrition. For a detailed look at the progress made toward understanding the host-microbiome interplay and the efforts undertaken to achieve a steady state of mutualism for a larger human health benefit, The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps in developing personalized microbiome-based therapies. Attendees will have the opportunity to interact with experts, ask questions, and seek advice on topics related to their research.

Topics to be covered:

  • Mechanisms by which human microbiota influence health and disease
  • How multidimensional data are being employed to develop personalized therapies

Meet the Speakers:

Eran Elinav, PhD
Professor, Department of Immunology
Weizmann Institute of Science, Israel

 

 

Eran Segal, PhD
Professor, Department of Mathematics and Computer Science
Weizmann Institute of Science, Israel

 

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!